Charts Week Month
Heat map Market Overview
Sentiment Sectors ETFs
Earnings News Earnings Movers The Drift Pivots
The Big Picture Breakouts Full Earnings News
Investor Services

Earnings are the driver of stock prices and the right earnings information can help longer-term investors significantly outperform the overall stock market.

The Whisper Report ® A look at upcoming earnings from both a top-down and bottom-up basis. Grades Stocks with A+ Earnings Whisper Grades Have Significantly Outperformed the Stock Market. Call Summaries Conference call summaries. AI Call Analysis AI Conference call analysis. Earnings Daily earnings results. Guidance Daily earnings guidance from companies. Reactions Earnings Screener Short Interest Report When the short trade becomes crowded.
Trader Service

Short-term earnings trading tools built around expectations, sentiment, quantitative studies, volatility, and post-earnings drift.

Trading Strategy The current strategy based on a broad market analysis and data. Earnings Whisper Plays Combining research, sentiment, quantitative studies, and technical analysis for short-term trades. Scores Identifying the likely Earnings Announcement Premium. Power Ratings Earnings with enough power for a short-term Post-Earnings Announcement Drift. Whisperings ^TM Whisperings are comments from analysts about upcoming earnings releases. AI Call Rankings Find which companies had the strongest or weakest conference calls. Option Trades Volatility Options Activity Unusual options activity around earnings. Setups Unusual options activity around earnings. Reversals Unusual options activity around earnings. Spikes Unusual options activity around earnings.
Dashboard

JNJ Johnson & Johnson

NYSE

$260.35

Johnson & Johnson (JNJ) Earnings News

Earnings press releases and Earnings Whispers previews for Johnson & Johnson (JNJ), newest first.

Wednesday July 29, 2026 5:42 PM ET

Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation

Wednesday July 29, 2026 5:28 PM ET

Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset

Wednesday July 15, 2026 6:20 AM ET

Johnson & Johnson reports Q2 2026 results, raises 2026 outlook

Wednesday May 27, 2026 4:22 PM ET

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

Tuesday April 14, 2026 6:20 AM ET

Johnson & Johnson reports Q1 2026 results, raises 2026 outlook

Wednesday March 18, 2026 7:49 AM ET

FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

Monday March 2, 2026 4:30 PM ET

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results